Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies

被引：0
|
作者：
Jinqi Huang
Stepanov Alexey
Jian Li
Terri Jones
Geramie Grande
Lacey Douthit
Jun Xie
Danna Chen
Xiaolei Wu
Maschan Michael
Changchun Xiao
Jiangning Zhao
Xuehua Xie
Jia Xie
Xiao Lei Chen
Guo Fu
Gabibov Alexander
Chi-Meng Tzeng
机构：
[1] Xiamen University,Translational Medicine Research Center (TMRC), School of Pharmaceutical Sciences
[2] The Scripps Research Institute,Department of Chemistry
[3] Russian Academy of Sciences,M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry
[4] Xiamen University,State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences
[5] The Affiliated Hospital of Putian University,Department of Immunology and Microbiology
[6] ProteinT Biotechnology Ltd. Co. Tianjin Airport Free Trade Zone,Department of Hematology
[7] Dmitrii Rogachev Federal Research Center for Pediatric Hematology,Department of Oncology
[8] Oncology and Immunology,School of Pharmacology
[9] The Scripps Research Institute,undefined
[10] zhongshan Hospital of Xiamen University,undefined
[11] The first hospital of Putian City,undefined
[12] Nanjing Tech University,undefined
来源：
Leukemia | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2315 / 2319
页数：4
相关论文
共 50 条
  • [31] T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
    Hu, Jingqiong
    Dunbar, Cynthia E.
    BLOOD, 2024, 144 (24) : 2473 - 2481
  • [32] Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies
    Vandghanooni, Somayeh
    Eskandani, Morteza
    Sanaat, Zohreh
    Omidi, Yadollah
    LIFE SCIENCES, 2022, 309
  • [33] T cell receptor CDR3 sequences and recombinant T cell receptors
    Slawomir, S
    FriedlHajek, R
    Siemann, U
    Ebner, C
    Scheiner, O
    Breiteneder, H
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1997, 113 (1-3) : 170 - 172
  • [34] T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines
    Farace, F
    Angevin, E
    Poullion, I
    Leboullaire, C
    Ferir, G
    Elias, D
    Escudier, B
    Triebel, F
    INTERNATIONAL JOURNAL OF CANCER, 1997, 71 (06) : 972 - 977
  • [35] T cells to a dominant epitope of GAD65 express a public CDR3 motif
    Quinn, Anthony
    McInerney, Marcia
    Huffman, Donald
    McInerney, Brigid
    Mayo, Stella
    Haskins, Kathryn
    Sercarz, Eli
    INTERNATIONAL IMMUNOLOGY, 2006, 18 (06) : 967 - 979
  • [36] Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
    Tao, Zhongfei
    Chyra, Zuzana
    Kotulova, Jana
    Celichowski, Piotr
    Mihalyova, Jana
    Charvatova, Sandra
    Hajek, Roman
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [37] CAR-T cell combination therapies in hematologic malignancies
    Zhou, Delian
    Zhu, Xiaojian
    Xiao, Yi
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [38] Secondary Malignancies after CAR-T Cell Therapy
    Rudek, Loreen Sophie
    Alakus, Hakan
    ONKOLOGIE, 2025, 31 (01): : 110 - 111
  • [39] Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies
    Abbasi, Samane
    Totmaj, Milad Asghari
    Abbasi, Masoumeh
    Hajazimian, Saba
    Goleij, Pouya
    Behroozi, Javad
    Shademan, Behrouz
    Isazadeh, Alireza
    Baradaran, Behzad
    CANCER MEDICINE, 2023, 12 (07): : 7844 - 7858
  • [40] A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families
    Wang, Jie
    Urbanska, Katarzyna
    Sharma, Prannda
    Poussin, Mathilde
    Nejati, Reza
    Shaw, Lauren
    Lim, Megan S.
    Schuster, Stephen J.
    Powell, Daniel, Jr.
    BLOOD, 2020, 136
12345